Drug Profile

IBIO 600

Alternative Names: IBIO-600

Latest Information Update: 14 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstralBio
Developer iBio Inc
Class Monoclonal antibodies; Obesity therapies
Mechanism of Action Myostatin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Obesity

Most Recent Events

28 Jan 2025 Preclinical trials in Obesity in USA (SC) before January 2025 (iBio pipeline, January 2025)
02 Jan 2025 IBIO 600 licensed to iBio
02 Jan 2025 iBio plans clinical trial for Obesity, Cardiovascular disorders and Metabolic disorders [Parenteral] in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com